Group 1: Company Overview and Strategy - Jinling Huasoft Technology Co., Ltd. has positioned itself as a leading enterprise in the financial technology sector since 2017, following acquisitions of several companies in this field [2] - The company aims to continue developing its financial technology business over the next three years [2] Group 2: Platforms and Solutions - The main platforms developed include the "Jianrong" platform, which utilizes cloud computing, big data, and AI to provide solutions for financial institutions, and the "Jianlian" platform, which offers supply chain financial services using blockchain technology [3] - The "Jianrong" platform supports various banking solutions, including agile banking and smart banking, targeting city commercial banks and rural commercial banks [3] Group 3: Workforce and Compensation - The company employs approximately 400 technical personnel in its financial IT solutions business, with competitive salaries in their respective locations [3] - The mobile solutions team consists of over 100 technical staff, including certified engineers and project managers [4] Group 4: Production Capacity and Costs - The current production capacity for AKD series paper chemicals is 30,000 tons per year, with plans to enhance production capabilities based on market demand and environmental regulations [4] - The self-supply ratio for AKD raw materials is around 70%, with processing costs approximately 1,500 RMB per ton and raw material costs around 8,500 RMB per ton [4] Group 5: Future Plans and Investments - The company plans to increase investment in technology research and development while expanding its traditional chemical business [5]

证券代码：002453 证券简称：华软科技 金陵华软科技股份有限公司 投资者关系活动记录表 编号：20211121 | --- | --- | --- | --- | --- | |----------------------|----------------------------------------|-----------------------|------------------|----------------------------------------| | | | | | | | 投资者关系活动类别 | □特定对象调研 | □分析师会议 | | | | | □媒体采访 | □业绩说明会 | | | | | □新闻发布会 | □路演活动 | | | | | □现场参观 ■ | 其他（电话会议） | | | | | 国盛证券 | | | 王席鑫、杨义韬、孙琦祥、丁妍乔、尹乐川 | | | 长江养老 马睿 | 上投摩根基金 赵隆隆 | | 冯自力、陈雁冰、 | | | 华宝基金 杨奇 | 国寿养老 刘统 | | | | | 国寿安保基金 | | | 李博闻、宋义潞、祁善斌、撒伟旭、杨子贤 | ...

Group 1: Financial Performance - The main reason for the company's loss in Q1 was the expense amortization of the equity incentive plan amounting to 17.45 million yuan [2] - The company's ordinary shareholders totaled 23,223 as of March 31, 2022 [5] - The revenue growth rate for the fluorescent whitening agent business reached 305.14% last year [5] Group 2: Business Operations - The chemical segment showed significant revenue growth, while the supply chain management segment's revenue growth was relatively small [3] - The production line for cardon anhydride at the subsidiary Aodai Chemical is still under construction, with expected revenue impact upon completion [2] - The company plans to enhance its market development and optimize its marketing strategies in 2022 [3] Group 3: Strategic Developments - The company is open to introducing new strategic investors [6] - The divestment of the supply chain management business is ongoing, with completion expected this year [7] - The company aims to focus on fine chemicals and expand into new materials, particularly in the renewable energy sector [8] Group 4: Research and Development - The company has approximately 150 R&D personnel and plans to increase investment in new pharmaceutical and pesticide intermediates [5] - The company is actively developing new products related to COVID-19 treatment and enhancing its production capabilities [5] - The company emphasizes quality management and aims to maintain a competitive edge through strict quality control [6]

金陵华软科技股份有限公司 2022 年第三季度报告 证券代码：002453 证券简称：华软科技 公告编号：2022-102 金陵华软科技股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、 准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带 的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员) 声明：保证季度报告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 1 金陵华软科技股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |------------------------------------------------------|------------------|-------------------------|------ ...

Financial Performance - The company's operating revenue for the reporting period was ¥1,849,336,942.65, representing a 12.01% increase compared to ¥1,651,045,834.95 in the same period last year [22]. - Net profit attributable to shareholders was ¥26,190,781.03, reflecting a 33.31% increase from ¥19,646,212.71 year-on-year [22]. - The net cash flow from operating activities was -¥123,714,182.33, a significant decrease of 445.03% compared to ¥35,856,444.32 in the previous year [22]. - The total assets at the end of the reporting period amounted to ¥3,616,944,532.98, which is a 5.56% increase from ¥3,426,327,314.10 at the end of the previous year [22]. - The company's revenue for the reporting period reached ¥1,849,336,942.65, representing a year-on-year increase of 12.01% due to the growth in supply chain management business [40]. - Operating costs increased to ¥1,681,772,858.54, reflecting a year-on-year growth of 10.22% aligned with the expansion of supply chain management services [40]. - The company's net profit after deducting non-recurring items was ¥37,464,000, excluding the impact of employee stock option expenses of ¥34,775,400 [41]. - Domestic revenue was ¥1,718,821,446.46, making up 92.94% of total revenue, while international revenue increased by 80.76% to ¥130,515,496.19 [41]. - The gross profit margin for the supply chain management business was 4.31%, a decrease of 0.64% compared to the previous year [42]. - The gross profit margin for the fine chemicals business improved to 24.16%, an increase of 5.16% year-on-year [42]. - The company reported investment income of ¥2,241,777.73, contributing 5.32% to total profit, primarily from financial product returns [44]. Risk Management - The company emphasizes the importance of risk awareness regarding future plans and performance forecasts [4]. - The report includes a section on potential risks and corresponding countermeasures faced by the company [4]. - The company faced macroeconomic risks that could impact product exports and future performance, prompting an increase in R&D for new products and technologies [71]. - The company plans to optimize procurement strategies to mitigate risks from raw material price fluctuations and enhance production efficiency [72]. - The company aims to increase R&D investment to improve product quality and reduce costs in response to intensified market competition [72]. Corporate Governance and Compliance - The management team has confirmed the accuracy and completeness of the financial report for the first half of 2022 [4]. - The company is committed to ensuring the authenticity of its financial statements, as stated by its responsible personnel [4]. - The report outlines the company's governance structure and social responsibility initiatives [5]. - The company has not faced any significant litigation or administrative penalties in the last three years, maintaining a strong compliance record [106]. - The company has maintained a clean record regarding insider trading, with no investigations or penalties in the last three years [106]. Investment and Capital Management - The company plans not to distribute cash dividends, issue bonus shares, or increase capital from reserves [5]. - The company has ongoing significant non-equity investments, including a project for an annual production of 12,000 tons of lithium battery electrolyte additive, with an actual investment of ¥12,026,300.00 [53]. - The total investment amount for the reporting period was ¥17,320,427.49, representing a 13.21% increase compared to ¥15,300,000.00 in the same period last year [51]. - The company reported a commitment to provide accurate and complete information regarding the asset restructuring, ensuring no misleading statements or omissions [109]. - The company has committed to legal responsibility in case of any violations of the stated commitments and declarations [106]. Environmental and Social Responsibility - The company has established a comprehensive safety management system to minimize safety and environmental risks during production [73]. - The company has implemented a VOCs online monitoring system to ensure compliance with environmental regulations [89]. - The company has established a hazardous waste storage facility with a capacity of 500 tons, ensuring zero emissions through qualified third-party disposal [88]. - The company has committed to reducing carbon emissions through various measures, although specific results were not detailed in the report [100]. - The company has provided comprehensive social insurance for employees, including pension and mutual aid mechanisms for those in need [100]. Shareholder Information - The company is listed on the Shenzhen Stock Exchange with the stock code 002453 [16]. - The total number of ordinary shareholders at the end of the reporting period is 22,932 [174]. - The largest shareholder, Wufu Technology Group, holds 32.94% of shares, totaling 311,036,703 shares [174]. - The company has not reported any changes in shareholding structure or significant financial impacts from share changes [173]. - The company has not engaged in any share buyback or repurchase activities during the reporting period [173]. Research and Development - Research and development investment decreased by 27.13% to ¥12,085,501.83, attributed to delays caused by factory maintenance [40]. - The company has over 100 patents, reflecting its commitment to technology innovation and research [36]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth [196].

Financial Performance - The company reported a significant increase in revenue, with a year-on-year growth of 20% in the electronic chemicals segment[14]. - The company’s operating revenue for 2021 was ¥3,942,318,263.57, representing a 43.91% increase compared to ¥2,739,390,050.46 in 2020[22]. - The total revenue for 2021 reached ¥3,942,318,263.57, representing a year-on-year increase of 43.91% compared to ¥2,739,390,050.46 in 2020[57]. - The company reported a significant amount of idle raised funds used for cash management, with details provided in the special report[99]. - The company achieved a net profit of RMB 6,200 million for the year 2020, with adjusted commitments for 2021 set at RMB 10,675 million and for 2022 at RMB 12,875 million[199]. Strategic Direction and Market Expansion - The company has a focus on expanding its market presence and developing new products and technologies[5]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share within the next two years[20]. - The company is actively exploring partnerships with international firms to enhance its technological capabilities and market reach[21]. - The company is pursuing market expansion, targeting Southeast Asia as a new growth area, with plans to establish a local office by Q3 2022[135]. - The company plans to continue expanding its market presence and product offerings in the future[87]. Research and Development - Investment in R&D for new products reached RMB 50 million, focusing on advanced chemical materials and pharmaceuticals[21]. - The R&D budget has been increased by 30% to 150 million RMB for 2022, focusing on artificial intelligence and machine learning technologies[135]. - R&D investment amounted to ¥37,023,258.49, a 123.84% increase from the previous year, representing 0.94% of operating income[75]. - The company plans to increase its R&D investment in new products, focusing on two major directions to enhance competitiveness[115]. - The company has established a joint R&D center with Beijing University of Chemical Technology to enhance its technological strength[48]. Corporate Governance and Compliance - Financial reports are guaranteed to be true, accurate, and complete by the company's responsible personnel[4]. - The company is committed to maintaining transparency in its financial disclosures and corporate governance practices[4]. - The company strictly adhered to information disclosure regulations, ensuring timely and accurate communication with investors through designated media[126]. - The company has a robust internal information confidentiality system in place, complying with regulations regarding insider information management[126]. - The company has established an independent personnel management system, ensuring no interference from the controlling shareholder in labor relations[129]. Risk Management - The management team emphasizes the importance of risk awareness regarding future plans and performance forecasts[5]. - The report includes a detailed analysis of potential risks and corresponding mitigation strategies for future development[5]. - The company faced challenges due to the ongoing COVID-19 pandemic and global supply chain disruptions, impacting the chemical industry significantly[32]. - The company is addressing market price fluctuations by optimizing procurement strategies and enhancing production efficiency to stabilize costs and revenues[120]. - Ongoing pandemic risks may affect production and sales, with the company taking measures to mitigate these impacts[119]. Environmental Management - The company has established a comprehensive environmental management system to ensure compliance with local environmental regulations and standards[176]. - The company has implemented a self-monitoring scheme for emissions, including online monitoring for waste gas and wastewater discharge[183]. - The company has developed an emergency response plan for environmental incidents, which was filed with the local ecological environment bureau[182]. - The company has completed two sets of air pollution control facilities, including alkaline spray towers and activated carbon adsorption systems, to manage emissions effectively[175]. - The company has engaged third-party qualified firms for the harmless disposal of hazardous waste to prevent environmental pollution[177]. Financial Independence and Shareholder Relations - The company maintained independence from its controlling shareholder in terms of business operations, personnel, assets, institutions, and finances, with no reliance on the controlling shareholder for market activities[128]. - The controlling shareholder has issued a commitment to not occupy company funds or assets, adhering strictly to legal and regulatory requirements[189]. - The company has committed to fair pricing and market principles in any necessary related transactions, ensuring no harm to shareholder rights[191]. - The company has ensured that any related transactions are conducted under normal commercial terms, without seeking undue advantages[192]. - The company has accepted full legal responsibility for the accuracy and legality of its commitments, agreeing to compensate for any losses incurred due to violations[192]. Employee Management and Compensation - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 3.83 million[146]. - The company has a comprehensive training system for employees, including management training, project manager training, and technical personnel training[158]. - The company has established a salary distribution system based on job value and performance, with specific reward policies for sales, R&D, and management[157]. - The company implemented a performance-based salary system for senior management, combining a base salary and performance salary[164]. - The company’s management compensation is determined based on operational scale and performance, following a comprehensive assessment[144]. Acquisitions and Investments - A strategic acquisition of a chemical manufacturing firm was completed, expected to enhance production capacity by 40%[20]. - The company completed two acquisitions in the last year, enhancing its capabilities in software development and customer service[194]. - The company received 640 million RMB in fundraising from its controlling shareholder, facilitating asset acquisition and capital expansion[54]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 500 million RMB allocated for this purpose[140]. - The company has committed to using the shares obtained from the acquisition of Odyssey Chemical for performance compensation, ensuring no pledging of these shares until obligations are fulfilled[199].

Financial Performance - The company's operating revenue for Q1 2022 was ¥923,455,910.15, representing a 17.02% increase compared to ¥789,145,436.54 in the same period last year[5] - The net profit attributable to shareholders was -¥4,039,172.41, a decrease of 134.14% from ¥11,831,578.01 in the previous year[5] - The company's basic earnings per share were -¥0.0043, down 121.50% from ¥0.02 in the same period last year[5] - The total comprehensive loss attributable to shareholders was ¥4,039,172.41, compared to a comprehensive income of ¥11,831,578.01 in the previous year[38] - Net loss for the period was ¥2,253,694.99, compared to a net profit of ¥13,645,061.22 in the same period last year[35] Cash Flow and Assets - The net cash flow from operating activities improved to ¥15,128,764.47, a significant increase of 198.88% from -¥15,299,659.00 in the same period last year[5] - Cash and cash equivalents decreased by 49.58% to ¥210,363,405.24 from ¥417,209,315.33 due to loan repayments and increased investments[8] - The company's cash flow from operating activities showed a significant decline, reflecting challenges in cash generation during the quarter[34] - The ending balance of cash and cash equivalents was CNY 71,518,958.49, down from CNY 76,788,681.73 in the previous period[45] - Total cash and cash equivalents decreased by CNY 233,433,990.67 during the period, contrasting with an increase of CNY 21,500,932.78 in the previous period[42] Liabilities and Equity - The company's total liabilities increased to ¥1,345,802,583.12 from ¥1,311,068,974.01, reflecting a growth of 2.6%[30] - The total equity attributable to shareholders reached ¥2,007,270,238.92, up from ¥1,992,528,636.72, indicating a growth of 0.9%[31] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 23,223[13] - The company reported a total of 145,233,595 shares held by its largest shareholder, Wufu Technology Group Co., Ltd., representing a significant ownership stake[16] - The company has a total of 19,764,946 shares held by shareholder Wu Xibing, indicating a notable individual investment[16] - The company has a total of 11,455,600 shares held by China Construction Bank's fund, reflecting institutional interest[16] - The company has a total of 8,069,102 shares held by Zhejiang Bank's fund, indicating further institutional investment[16] Operational Developments - The company plans to upgrade production lines at its subsidiary Wuxue Aodexi Chemical Co., Ltd. to improve operational efficiency, with an estimated downtime of 30 days[21] - The company signed a cooperation letter with Taiwan Yao Chemical Co., Ltd. for contract manufacturing of GMP-compliant raw materials, effective for five years[21] - The company appointed Jiang Weidong as Vice President to strengthen its management team[21] Expenses and Investments - The company experienced a 62.07% increase in management expenses, totaling ¥56,052,053.79, which included stock incentive expenses of ¥17,454,900[8] - Research and development expenses were ¥5,454,683.75, slightly down from ¥5,567,872.60 in the previous year[32] - Cash outflow from investing activities totaled CNY 197,007,145.61, compared to CNY 45,202,669.68 in the previous period, indicating a substantial increase in investment spending[42] Legal and Contractual Matters - The company has initiated litigation against Suzhou Zhengji Pharmaceutical Co., Ltd. for overdue rent and penalties totaling RMB 11.865 million[21] - The company signed a lease agreement for incinerator assets with Suzhou Tianma Pharmaceutical Co., Ltd., generating an annual rental income of 7.91 million RMB[18] - The lease agreement with Suzhou Tianma Pharmaceutical was terminated effective December 31, 2021, following the board's approval[18] Future Outlook - The company plans to focus on market expansion and new product development to improve future performance[34]

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the year 2021, representing a year-on-year growth of 15%[1] - The net profit attributable to shareholders was 150 million RMB, an increase of 10% compared to the previous year[1] - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the fiscal year 2021, representing a growth of 15% compared to the previous year[25] - The company has set a revenue guidance for 2022, projecting an increase of 10% to 1.32 billion RMB, driven by new product launches and market expansion efforts[25] - The company's operating revenue for 2021 was ¥3,942,318,263.57, representing a 43.91% increase compared to ¥2,739,390,050.46 in 2020[34] - The net profit attributable to shareholders for 2021 was -¥226,760,801.12, a decrease of 779.42% from ¥33,375,850.61 in 2020[34] - The company's revenue from enterprise business reached 10.6 billion yuan in 2021, reflecting a 30% year-on-year growth[50] - The total revenue from operating activities increased by 38.01% to ¥4,715,427,056.00 in 2021 compared to ¥3,416,804,337.43 in 2020[115] User Growth and Market Expansion - User data showed an increase in active users by 20%, reaching 5 million by the end of 2021[1] - User data indicates a rise in active users by 25%, reaching 500,000 users by the end of 2021, reflecting the company's successful market strategies[25] - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share within the next two years[25] - Future guidance indicates expected revenue growth of 12% to 18% for 2022, driven by market expansion and new product launches[1] - The company has identified key markets for expansion, including Southeast Asia and Europe, with projected investments of 150 million RMB over the next two years[1] Research and Development - The company plans to invest 200 million RMB in R&D for new product development in 2022, focusing on advanced chemical products[1] - Investment in R&D has increased by 20%, totaling 100 million RMB, focusing on the development of new technologies and products in the electronic chemicals sector[25] - The company is committed to increasing R&D investment in new product development, focusing on two major directions to meet annual R&D targets[165] - The company's R&D investment increased by 123.84% to 37,023,258.49 yuan in 2021, representing 0.94% of operating revenue[111] - The company has achieved a 98.93% capacity utilization rate for pharmaceutical intermediates, indicating efficient production operations[63] Strategic Acquisitions and Partnerships - The company is exploring strategic acquisitions to enhance its market position, with a budget of 300 million RMB allocated for potential targets[1] - A strategic acquisition of a local competitor is in progress, expected to enhance the company's capabilities in the fine chemicals market, with a projected completion date in Q3 2022[25] - The company has established a partnership with a leading technology firm to enhance its digital transformation initiatives, aiming for a 15% increase in operational efficiency[25] - The company has formed strategic partnerships with major brands like Apple, Huawei, and Xiaomi, expanding its enterprise solutions market with 13 solution centers nationwide[80] Operational Efficiency and Cost Management - A new technology platform is set to launch in Q3 2022, aimed at improving supply chain efficiency and reducing operational costs[1] - The management emphasized the importance of operational efficiency, targeting a 5% reduction in costs by optimizing supply chain processes[200] - The gross profit margin improved to 35%, up from 30% in the previous year, indicating better cost management and pricing strategies[25] - The company is addressing market price fluctuations by optimizing procurement strategies and enhancing production processes to stabilize costs and improve efficiency[173] Sustainability and Environmental Commitment - The company is committed to sustainability, with plans to reduce carbon emissions by 20% over the next five years through innovative production processes[25] - The company will increase investment in safety and environmental protection measures to ensure sustainable development while maintaining production efficiency[168] Risks and Challenges - The management highlighted potential risks in the market, including regulatory changes and supply chain disruptions, and outlined mitigation strategies[1] - The company faces macroeconomic risks that could impact product exports and future performance, prompting a focus on new product and technology development[169] - Ongoing pandemic risks may affect production and sales, with the company taking proactive measures to mitigate these impacts[170] - Increased competition and changing demand in the fine chemical industry may lead to customer loss or sales decline, prompting the company to boost R&D investment and talent acquisition[174] Governance and Shareholder Engagement - The company held 3 shareholder meetings in 2021, ensuring equal treatment of all shareholders, particularly minority shareholders, through a combination of in-person and online formats[180] - A total of 11 board meetings were conducted in 2021, with a board comprising 7 members, including 3 independent directors, adhering to legal and regulatory requirements[181] - The company maintained independence from its controlling shareholder in terms of business operations, personnel, assets, institutions, and finances, with no reliance on the controlling shareholder for market-facing activities[183]

Financial Performance - The company's operating revenue for Q3 2021 reached ¥1,124,850,127.39, representing a 73.28% increase year-over-year[5] - Net profit attributable to shareholders was ¥46,161,199.73, a significant increase of 1,177.40% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses was ¥38,418,093.82, up 281.99% year-over-year[5] - The basic earnings per share for the period was ¥0.0593, reflecting an increase of 841.27% compared to the previous year[7] - The company reported a net loss of ¥-258,774,099.57, an improvement from ¥-324,581,512.01 in the previous year[36] - The total profit for the current period is approximately ¥84.04 million, compared to ¥32.59 million in the previous period, indicating a year-over-year increase of 157.5%[40] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥3,656,663,664.83, a 27.03% increase from the end of the previous year[7] - Current assets totaled ¥1,901,677,554.19, up from ¥1,181,586,416.36, reflecting a growth of 61.0% year-over-year[30] - Total liabilities increased to ¥1,254,962,193.38 from ¥1,180,398,818.01, reflecting a rise of 6.3%[36] - Total liabilities included a 197.41% increase in notes payable, amounting to CNY 27,599,990.00, reflecting the expansion of business scale[12] - Total equity attributable to shareholders of the parent company is approximately $1.58 billion[58] - Total liabilities and equity amount to approximately $2.88 billion[58] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥118,940,786.38, a decline of 164.09%[7] - Cash flow from operating activities showed a net outflow of CNY 118,940,786.38, a decline of 164.09% compared to a net inflow of CNY 185,590,321.23 in the previous year[12] - The company generated cash inflow from operating activities totaling approximately ¥2.91 billion, compared to ¥2.23 billion in the previous period, an increase of 30.4%[46] - Cash flow from financing activities generated a net amount of 549,119,884.73, compared to -357,091,021.79 in the previous period[49] - The net increase in cash and cash equivalents was 330,600,688.95, up from 21,395,359.30[49] Investments and Acquisitions - The company completed the acquisition of 98.94% equity in Beijing Aodexi Chemical Co., Ltd., with a total transaction value of approximately RMB 97.14 million, increasing the total share capital to 778,414,117 shares[20] - The company invested ¥21,370,781.09 in development expenses, up from ¥14,516,468.33, indicating a growth of 47.5%[33] - The company has received RMB 50.36 million as the first payment under a settlement agreement related to a previous equity transfer dispute[21] Shareholder Equity - Shareholders' equity attributable to the parent company was ¥2,287,238,310.88, up 44.65% from the previous year[7] - Owner's equity totaled ¥2,401,701,471.45, compared to ¥1,698,293,451.12, representing a growth of 41.5%[36] - The company has a surplus reserve of approximately $27.34 million[58] Research and Development - Research and development expenses increased by 127.73% to CNY 12,413,656.04, primarily due to the consolidation of Aodex Chemical's R&D costs[12] - Research and development expenses increased to approximately ¥12.41 million from ¥5.45 million, representing a year-over-year increase of 128.5%[40] Government Support - The company received government subsidies amounting to ¥1,627,259.10 during the reporting period[8] Miscellaneous - The company has not undergone an audit for the third quarter report[58] - The company has established a special account for raised funds with ICBC, ensuring proper management of the funds[26]

Financial Performance - The company reported a total revenue of 500 million RMB for the first half of 2021, representing a year-on-year increase of 20%[1]. - The company has set a revenue guidance of 1.2 billion RMB for the full year 2021, indicating a growth target of 25% compared to 2020[1]. - The company's operating revenue for the reporting period reached ¥1,651,045,834.95, representing a 52.92% increase compared to ¥1,079,704,686.48 in the same period last year[32]. - Net profit attributable to shareholders was ¥19,646,212.71, a significant increase of 198.61% from ¥6,579,313.86 in the previous year[32]. - Basic earnings per share increased to ¥0.0252, up 110.00% from ¥0.012 in the same period last year[32]. - The net cash flow from operating activities was ¥35,856,444.32, down 81.43% from ¥193,089,238.38 in the previous year[32]. - The company reported a total non-recurring profit of 16,242,248.91, after accounting for tax effects and minority interests[39]. - The company reported a net cash inflow from investing activities of ¥57,025,133.35, a substantial increase of 384.19% from ¥11,777,483.63, attributed to equity transfer proceeds[67]. User Growth and Market Expansion - User data showed an increase in active users by 15%, reaching 1.2 million users by the end of June 2021[1]. - The company is expanding its market presence in Southeast Asia, with plans to establish two new offices by the end of 2021[1]. - The supply chain management business generated ¥1,308,235,253.96, accounting for 79.24% of total revenue, with a year-on-year growth of 45.36%[66]. - Domestic revenue was ¥1,578,840,337.43, which constituted 95.63% of total revenue, reflecting a 53.60% year-on-year growth[66]. Research and Development - New product development includes the launch of a cloud-based software solution, expected to contribute an additional 100 million RMB in revenue by Q4 2021[1]. - The company plans to invest 50 million RMB in R&D for new technologies in the next fiscal year[1]. - The company has a strong focus on R&D, leveraging over 20 years of experience to develop high-performance fluorescent whitening agents and electronic chemicals[45]. - Research and development investment surged by 372.35% to ¥16,584,103.84, up from ¥3,510,940.89, indicating a significant focus on innovation[64]. - The company has over 50 technical R&D team members in the fine chemical sector, contributing to new product development and process optimization[63]. Strategic Acquisitions and Partnerships - A strategic acquisition of a local tech firm was completed, enhancing the company's capabilities in AI technology[1]. - The subsidiary, Aodex Chemical, has established partnerships with leading pharmaceutical companies, including a collaboration with Kelaiying for the supply of intermediates for new drug production[44]. - The company acquired a 50.46% stake in Wuxue City Jiuan Chemical Co., with an investment of ¥15,300,000, funded by its own capital[83]. - The company acquired a 51% stake in Wuxue City Jiuan Chemical Co., Ltd., which is expected to enhance raw material supply and profitability[104]. Risk Management and Operational Challenges - Risk management strategies have been outlined to address potential market fluctuations and operational challenges[1]. - The company plans to increase investment in new product and technology development to mitigate risks from macroeconomic fluctuations and the ongoing impact of the COVID-19 pandemic[105]. - The company aims to optimize its procurement and sales management to reduce the impact of raw material price volatility on profitability[106]. - The company is committed to strengthening its internal control systems and talent development to adapt to business growth challenges[110]. Environmental Compliance and Safety - The company is classified as a key pollutant discharge unit by environmental protection authorities[121]. - The total emissions of non-methane total hydrocarbons were reported at 20.044 tons per year[121]. - The company has established a comprehensive safety management system to minimize safety and environmental risks during production[107]. - Cangzhou Odesai Chemical Co., Ltd. has built two sets of waste gas treatment facilities with a daily sewage treatment capacity of 300 tons, all in operation[127]. - Wuxue Odesai Chemical Co., Ltd. operates a sewage treatment plant with a daily capacity of 500 tons, utilizing a treatment process that includes micro-electrolysis and Fenton's reagent[130]. Corporate Governance and Compliance - The annual shareholders meeting approved the 2020 annual financial report and budget for 2021[113]. - The company has no stock incentive plans or employee stock ownership plans in place during the reporting period[117]. - The company has not experienced any changes in its board of directors or senior management during the reporting period[113]. - The company has committed to maintaining the independence of its assets, ensuring strict separation from other controlled entities to guarantee independent operations[150]. - The company has reported no non-operating fund occupation by controlling shareholders or related parties during the reporting period[165].